Literature DB >> 22553346

Chemokine (C-X-C motif) ligand 12 is associated with gallbladder carcinoma progression and is a novel independent poor prognostic factor.

Hyun Jung Lee1, Kyungmin Lee, Dong Gwang Lee, Kwang-Hee Bae, Jang-Seong Kim, Zhe Long Liang, Song Mei Huang, Yoon Suk Oh, Ha Yon Kim, Deog Yeon Jo, Jeong-Ki Min, Jin-Man Kim, Hyo Jin Lee.   

Abstract

PURPOSE: Although recent studies have suggested that chemokine (C-X-C motif) ligand 12 (CXCL12) is important in the progression of various malignancies, its role in gallbladder carcinoma (GBC) remains unknown. We investigated CXCL12 expression in GBC and its biologic and prognostic role in GBC tumorigenesis. EXPERIMENTAL
DESIGN: We examined CXCL12 expression in tumor specimens from 72 patients with GBC by immunohistochemistry and analyzed the correlation between CXCL12 expression and clinicopathologic factors or survival. The functional significance of CXCL12 expression was investigated by CXCL12 treatment and suppression of CXCR4, a major receptor of CXCL12, as well as by CXCL12 overexpression in in vitro and in vivo studies.
RESULTS: CXCL12 was differentially expressed in GBC tissues. CXCL12 expression was significantly associated with a high histologic grade (P = 0.042) and nodal metastasis (P = 0.015). Multivariate analyses showed that CXCL12 expression (HR, 8.675; P = 0.014) was an independent risk factor for patient survival. CXCL12 significantly increased anchorage-dependent and -independent growth, migration, invasion, adhesiveness, and survival of GBC cells in vitro, and these effects were dependent on CXCR4. Consistent with these results, overexpression of CXCL12 significantly promoted GBC tumorigenicity in a xenograft model.
CONCLUSIONS: Our results indicate that GBC cells express both CXCL12 and its receptor CXCR4, and CXCL12 may have a role in GBC progression through an autocrine mechanism. In addition, CXCL12 is a novel independent poor prognostic factor in patients with GBCs. Thus, targeting CXCL12 and CXCR4 may provide a novel therapeutic strategy for GBC treatment. ©2012 AACR.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22553346     DOI: 10.1158/1078-0432.CCR-11-2417

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  18 in total

1.  Cancer-associated fibroblast-derived CXCL12 causes tumor progression in adenocarcinoma of the esophagogastric junction.

Authors:  Hidetaka Sugihara; Takatsugu Ishimoto; Tadahito Yasuda; Daisuke Izumi; Kojiro Eto; Hiroshi Sawayama; Keisuke Miyake; Junji Kurashige; Yu Imamura; Yukiharu Hiyoshi; Masaaki Iwatsuki; Shiro Iwagami; Yoshifumi Baba; Yasuo Sakamoto; Yuji Miyamoto; Naoya Yoshida; Masayuki Watanabe; Hiroshi Takamori; Hideo Baba
Journal:  Med Oncol       Date:  2015-04-24       Impact factor: 3.064

2.  Wnt/β-catenin pathway is required for epithelial to mesenchymal transition in CXCL12 over expressed breast cancer cells.

Authors:  Shumei Shan; Qiang Lv; Yiling Zhao; Chunfeng Liu; Yingyan Sun; Kemin Xi; Jiayi Xiao; Caijuan Li
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

Review 3.  CXC chemokines and chemokine receptors in gastric cancer: from basic findings towards therapeutic targeting.

Authors:  Hyo Jin Lee; Ik-Chan Song; Hwan-Jung Yun; Deog-Yeon Jo; Samyong Kim
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

4.  Differential expression of SDF-1 isoforms in bladder cancer.

Authors:  Miguel Gosalbez; Marie C Hupe; Soum D Lokeshwar; Travis J Yates; John Shields; Muthu K Veerapen; Axel S Merseburger; Charles J Rosser; Mark S Soloway; Vinata B Lokeshwar
Journal:  J Urol       Date:  2013-11-26       Impact factor: 7.450

Review 5.  A meta-analysis for CXCR4 as a prognostic marker and potential drug target in non-small cell lung cancer.

Authors:  Changyuan Zhang; Jie Li; Yi Han; Jian Jiang
Journal:  Drug Des Devel Ther       Date:  2015-06-24       Impact factor: 4.162

6.  Bortezomib inhibits the survival and proliferation of bone marrow stromal cells.

Authors:  Ha-Yon Kim; Ji-Young Moon; Haewon Ryu; Yoon-Seok Choi; Ik-Chan Song; Hyo-Jin Lee; Hwan-Jung Yun; Samyong Kim; Deog-Yeon Jo
Journal:  Blood Res       Date:  2015-06-25

7.  Cancer-associated fibroblasts promote the progression of endometrial cancer via the SDF-1/CXCR4 axis.

Authors:  Fei Teng; Wen-Yan Tian; Ying-Mei Wang; Yan-Fang Zhang; Fei Guo; Jing Zhao; Chao Gao; Feng-Xia Xue
Journal:  J Hematol Oncol       Date:  2016-02-06       Impact factor: 17.388

Review 8.  A meta-analysis of CXCL12 expression for cancer prognosis.

Authors:  Harsh Samarendra; Keaton Jones; Tatjana Petrinic; Michael A Silva; Srikanth Reddy; Zahir Soonawalla; Alex Gordon-Weeks
Journal:  Br J Cancer       Date:  2017-05-23       Impact factor: 7.640

9.  Inhibition of infection-mediated preterm birth by administration of broad spectrum chemokine inhibitor in mice.

Authors:  Oksana Shynlova; Anna Dorogin; Yunqing Li; Stephen Lye
Journal:  J Cell Mol Med       Date:  2014-06-04       Impact factor: 5.310

10.  EVALUATION THE EXPRESSION OF THREE GENES TO EPITHELIAL OVARIAN CANCER RISK IN CHINESE POPULATION.

Authors:  Ju Huang; Hao Lin; Ming En Lin
Journal:  Afr J Tradit Complement Altern Med       Date:  2016-07-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.